RE:RE:RE:ConcentrationMugs, I'm certainly not arguing the potential could be much bigger but I'm more comfortable using past performance metrics for basic assumptions. A successful p2 for $4B chronic enabled the stock to peak around $400M (give or take) so 10% of peak US I believe is a fair assumption for successful p2 acute. I'd also imagine momentum traders will exit in that zone as well due to risk/reward reversal and opportunity cost. That certainly rewarded the traders in this last go round!